rs869312161

Variant summary

Our verdict is Uncertain significance. The variant received 3 ACMG points: 5P and 2B. PM1PM2PP2BP4_Moderate

The NM_000169.3(GLA):​c.989A>G​(p.Gln330Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q330E) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 23)
Exomes 𝑓: 0.0 ( 0 hom. 0 hem. )
Failed GnomAD Quality Control

Consequence

GLA
NM_000169.3 missense

Scores

2
1
14

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:3O:1

Conservation

PhyloP100: -0.455

Publications

5 publications found
Variant links:
Genes affected
GLA (HGNC:4296): (galactosidase alpha) This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties. [provided by RefSeq, Jul 2008]
RPL36A-HNRNPH2 (HGNC:48349): (RPL36A-HNRNPH2 readthrough) This locus represents naturally occurring read-through transcription between the neighboring ribosomal protein L36a and heterogeneous nuclear ribonucleoprotein H2 (H') genes on chromosome X. The read-through transcript produces a protein with similarity to the protein encoded by the upstream locus, ribosomal protein L36a. Alternatively spliced transcript variants have been identified. [provided by RefSeq, Jan 2011]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 3 ACMG points.

PM1
In a hotspot region, there are 18 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 15 uncertain in NM_000169.3
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 218 curated pathogenic missense variants (we use a threshold of 10). The gene has 17 curated benign missense variants. Gene score misZ: 1.8759 (below the threshold of 3.09). Trascript score misZ: NaN (below the threshold of 3.09). GenCC associations: The gene is linked to Fabry disease.
BP4
Computational evidence support a benign effect (MetaRNN=0.13124645).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GLANM_000169.3 linkc.989A>G p.Gln330Arg missense_variant Exon 6 of 7 ENST00000218516.4 NP_000160.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GLAENST00000218516.4 linkc.989A>G p.Gln330Arg missense_variant Exon 6 of 7 1 NM_000169.3 ENSP00000218516.4
RPL36A-HNRNPH2ENST00000409170.3 linkc.300+2923T>C intron_variant Intron 4 of 4 4 ENSP00000386655.4

Frequencies

GnomAD3 genomes
Cov.:
23
GnomAD2 exomes
AF:
0.00
AC:
0
AN:
183449
AF XY:
0.00
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
0.00
AC:
0
AN:
1086229
Hom.:
0
Cov.:
29
AF XY:
0.00
AC XY:
0
AN XY:
352607
African (AFR)
AF:
0.00
AC:
0
AN:
26173
American (AMR)
AF:
0.00
AC:
0
AN:
35193
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
19320
East Asian (EAS)
AF:
0.00
AC:
0
AN:
30162
South Asian (SAS)
AF:
0.00
AC:
0
AN:
53866
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
40510
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4077
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
831236
Other (OTH)
AF:
0.00
AC:
0
AN:
45692
GnomAD4 genome
Cov.:
23

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:3Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Fabry disease Uncertain:3
Sep 19, 2025
Genomenon, Inc, Genomenon, Inc
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

GLA c.989A>G is a missense variant that changes the amino acid at residue 330 from Glutamine to Arginine. This variant has been observed in at least one proband affected with Fabry disease (PMID:26415523;30739116). Functional studies have been reported; however, the significance of the findings remain unclear (PMID:26415523). It is absent or not present at a significant frequency in gnomAD. In silico models agree that this variant is not damaging. In conclusion, we classify GLA c.989A>G as a variant of unknown significance.

Jan 01, 2014
Albrecht-Kossel-Institute, Medical University Rostock
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:research

Jan 22, 2020
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:curation

The p.Gln330Arg variant in GLA has been reported in the literature in three males, whose clinical status for Fabry disease was uncertain (PMID: 26415523, 29330335, 28340804), and was absent from large population studies (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs869312161). This variant has also been reported in ClinVar as a VUS by the Albrecht-Kossel-Institute (Variation ID: 217409). In vitro functional studies provide some evidence that the p.Gln330Arg variant may not impact protein function (PMID: 26415523). However, these types of assays may not accurately represent biological function. Computational prediction tools, including splice predictors, and conservation analyses suggest that this variant may not impact the protein, though this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of p.Gln330Arg is uncertain. ACMG/AMP Criteria applied: PM2, BP4, BS3_supporting (Richards 2015).

Migalastat response Other:1
Jan 01, 2014
Albrecht-Kossel-Institute, Medical University Rostock
Significance:drug response
Review Status:no assertion criteria provided
Collection Method:research

Pharmacological Chaperone response: yes

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.050
CardioboostCm
Benign
0.0054
BayesDel_addAF
Benign
-0.22
T
BayesDel_noAF
Benign
-0.55
CADD
Benign
0.092
DANN
Benign
0.64
DEOGEN2
Uncertain
0.59
D;.
FATHMM_MKL
Benign
0.068
N
LIST_S2
Benign
0.45
T;T
M_CAP
Pathogenic
0.82
D
MetaRNN
Benign
0.13
T;T
MetaSVM
Pathogenic
1.3
D
MutationAssessor
Benign
-2.2
N;.
PhyloP100
-0.46
PrimateAI
Benign
0.24
T
PROVEAN
Benign
1.9
N;.
REVEL
Benign
0.22
Sift
Benign
1.0
T;.
Sift4G
Benign
1.0
T;.
Vest4
0.17
ClinPred
0.077
T
GERP RS
-4.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Varity_R
0.35
gMVP
0.87
Mutation Taster
=32/68
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs869312161; hg19: chrX-100653368; API